Trifarotene topical Side Effects
Medically reviewed by Drugs.com. Last updated on April 15, 2020.
For the Consumer
Applies to trifarotene topical: topical application cream
Side effects requiring immediate medical attention
Along with its needed effects, trifarotene topical may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking trifarotene topical:
- Itching or redness at the application site (severe)
- Dryness, discoloration, pain, or swelling at the application site
- skin rash, hives, itching, or redness
Side effects not requiring immediate medical attention
Some side effects of trifarotene topical may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Burning or stinging at the application site
For Healthcare Professionals
Applies to trifarotene topical: topical cream
Very common (10% or more): Application site/local tolerability worsened (erythema, scaling, dryness, stinging/burning)
Common (1% to 10%): Application site irritation, application site pruritus
Frequency not reported: Application site pain, application site dryness, application site discoloration, application site rash, application site swelling, application site erosion[Ref]
Application site tolerability was evaluated by active assessment of erythema, scaling, dryness, and stinging/burning and collected separately. In the 12-week phase 3 clinical trials, these signs/symptoms were assessed at baseline and at least once postbaseline. On the face, local tolerability worsened for any of the signs/symptoms compared with baseline to a score of moderate for up to 30% of patients or severe for up to 6% of patients; on the trunk, local tolerability worsened for any of the signs/symptoms compared with baseline to a score of moderate for up to 19% of patients or severe for up to 5% of patients. The scores reached maximum severity at week 1 and week 2 to 4 of therapy for the face and trunk, respectively, and decreased thereafter.[Ref]
Common (1% to 10%): Sunburn
1. "Product Information. Aklief (trifarotene topical)." Galderma Laboratories Inc, Cranbury, NJ.
More about trifarotene topical
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.